Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia.
about
Advances in the prevention, management, and treatment of community-acquired pneumoniaCardiotoxicity during invasive pneumococcal diseaseLessons learned from 2 decades of CAP therapy data: ways to improve patient managementUse of azithromycin and risk of ventricular arrhythmia.Risk of heart failure after community acquired pneumonia: prospective controlled study with 10 years of follow-upCardiac risks associated with antibiotics: azithromycin and levofloxacinAzithromycin associated with a reduction in 90-day mortality among older pneumonia patients, although a true clinical benefit is uncertainApplication of a methicillin-resistant Staphylococcus aureus risk score for community-onset pneumonia patients and outcomes with initial treatmentRegional variation in antibiotic prescribing among medicare part D enrollees, 2013Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis.Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial.Macrolide antibiotics and the risk of ventricular arrhythmia in older adults.Infiltrated Macrophages Die of Pneumolysin-Mediated Necroptosis following Pneumococcal Myocardial InvasionChromogranin A levels and mortality in patients with severe sepsisThe bacterial pneumonias: a new treatment paradigm.The Value of Macrolide-Based Regimens for Community-Acquired Pneumonia.Pharmacotherapy for community-acquired pneumonia in the elderly.Macrolide resistance mechanisms in Enterobacteriaceae: Focus on azithromycin.Clinical Management of Community Acquired Pneumonia in the Elderly Patient.Application of a Risk Score to Identify Older Adults with Community-Onset Pneumonia Most Likely to Benefit From Empiric Pseudomonas Therapy.Health care-associated pneumonia in the intensive care unit: Guideline-concordant antibiotics and outcomes.The potential of anti-infectives and immunomodulators as therapies for asthma and asthma exacerbations.Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia.Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study.Impact of the FDA Warning for Azithromycin and Risk for QT Prolongation on Utilization at an Academic Medical Center.The cardiovascular safety of azithromycin.Macrolide antibiotics for prevention of chronic obstructive pulmonary disease exacerbations: are we there yet?Editorial Commentary: The Mismatch Between Physicians' Expectations and Microbiologic Reality.The Association Between Major Depressive Disorder and Outcomes in Older Veterans Hospitalized With Pneumonia.Pneumonia as a cardiovascular disease.Macrolides: a promising pharmacologic therapy for chronic obstructive pulmonary disease.Appraisal of the cardiovascular risks of azithromycin: an observational analysis.Antimicrobials and QT prolongation.Inappropriate Use of Antimicrobials for Lower Respiratory Tract Infections in Elderly Patients: Patient- and Community-Related Implications and Possible Interventions.Estimated Cardiac Risk Associated With Macrolides and Fluoroquinolones Decreases Substantially When Adjusting for Patient Characteristics and Comorbidities.
P2860
Q26753138-A421EA4C-F034-4EAF-A12E-C03770E8A49EQ28081769-246F4412-F995-4224-B7C8-C8A74A536DFDQ31107743-9AC573E1-6187-4BB4-B3F6-058D7209D4E1Q33566195-680410AC-A7CC-4B98-80B1-D45B40A1F7C1Q33647377-400199C3-690F-4C7B-99FB-4F6EF26F458EQ35502601-A1329FB3-68CC-490E-98E3-A5821A9199A6Q35619295-BEE9AC82-393F-4F14-8D11-43681CD55E01Q35780916-79B9E61C-CED0-405C-B813-7AC4C058E792Q36219079-C681926A-FE20-4F22-9EEF-1EF3ABE4C00CQ36342810-CB3B6808-FC26-4B46-9DAF-0D01B335DDCFQ36406243-2A32E53D-D3F6-4D91-A9FE-F873231200DCQ36808701-BDAD2650-FAC5-4B3C-88DD-C9CCBAE2FBC0Q36888581-F5C2E5CE-D1A0-42B7-BC93-5610995AEFA0Q37264816-802BF30A-6C20-4008-AF7B-B453BD07CA28Q38307688-BCB3256A-11D0-4EB8-98A5-32988F98ED13Q38601840-5AFA8226-E4F0-4D52-A5E7-49946364BF9CQ38731918-6F7739D6-92A4-4D7D-8C1B-4E1E0378284FQ38804355-97D4F8F0-B1D2-4845-B8BC-3DD4428EA3A6Q38969066-292B007C-3205-459D-B528-41C1C43F8B06Q39051283-479DDC4A-838B-4A77-9974-9BF1A3A5A744Q39422204-1066F9DC-290C-40A6-B41B-15025053C984Q39444008-A677D197-D6CB-4B70-8B78-A29003E9D363Q40664555-8B231EEA-23FF-43C0-A21D-043DDA06DA77Q41656046-04A0F4AE-1755-4D39-9865-7456790051EBQ42576679-455E938F-1FB4-498F-9F74-21C1ECDF8AA2Q42952501-D090910A-E5FD-4459-B4A4-293997DC84B8Q42993138-38B9AFD5-5D51-4030-BF51-50B60D25592DQ43449557-7E3EAA32-F784-42CA-B266-B3549D2D379CQ47230698-662A1248-17D3-41AD-AA27-2110D7D547A7Q47658087-2E2EF45F-80DE-4845-8906-20666AE680D6Q48009990-151CF124-A696-445B-BD0B-02BD6DE2AB0BQ50272937-F06FE07F-E7E0-4706-A80D-D9546F66C475Q51153254-738F3F61-A70B-4341-A440-58D4ED76A6A8Q52584035-C03C9D7E-BDA1-4C95-9588-389AA509E671Q55411506-8906A287-CDB8-4857-A9AE-93F7A6E5810F
P2860
Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Association of azithromycin wi ...... s hospitalized with pneumonia.
@ast
Association of azithromycin wi ...... s hospitalized with pneumonia.
@en
type
label
Association of azithromycin wi ...... s hospitalized with pneumonia.
@ast
Association of azithromycin wi ...... s hospitalized with pneumonia.
@en
prefLabel
Association of azithromycin wi ...... s hospitalized with pneumonia.
@ast
Association of azithromycin wi ...... s hospitalized with pneumonia.
@en
P2093
P2860
P50
P921
P356
P1476
Association of azithromycin wi ...... s hospitalized with pneumonia.
@en
P2093
Antonio Anzueto
Carlos A Alvarez
Chester Good
Christopher R Frei
Christopher S Johnson
Ethan A Halm
John R Downs
Marcos I Restrepo
Mark Metersky
Michael J Fine
P2860
P304
P356
10.1001/JAMA.2014.4304
P407
P577
2014-06-01T00:00:00Z